Teva Appoints New Chief Executive After Months of Speculation - WSJ
Mylan/Viatris and Teva at the 38th Annual J.P. Morgan Healthcare Conference - MidgardFinance.com
Teva Pharmaceutical: Past Behind And A Promising 2023 (NYSE:TEVA) | Seeking Alpha
Teva eases debt burden with $400M tender offer as turnaround effort escalates | Fierce Pharma
Running out of time and money, CEO to prioritize getting Teva out of the hole | The Times of Israel
Teva Announces $2,250,000,000 Debt Tender Offers for Notes Due 2023-2026
Teva Reports Fourth Quarter and Full Year 2019 Financial Results | Business Wire
/arc-anglerfish-arc2-prod-pmn.s3.amazonaws.com/public/MOWBBPQDNNCQXCF67CU3KXSDS4.jpg "Teva seeks to shrink debt, grow with generic Viagra")
Teva seeks to shrink debt, grow with generic Viagra
High Debt, Potential Litigation Costs Face New Teva CFO - WSJ
Teva Announces $2,250,000,000 Debt Tender Offers for Notes Due 2023-2026 | Business Wire
Teva: This One Is Difficult (NYSE:TEVA) | Seeking Alpha
Can Teva's Debt Repayment Plan Deleverage Its Balance Sheet?
Teva (TEVA) Stock Is Still Facing Major Risk at This Point | InvestorPlace
Teva Pharmaceutical or Mylan: Which Has the Better Debt Profile?
Why Long-Term Investors Should Avoid Teva Stock | The Motley Fool
Teva CEO Resigns; Dividend Cut Should Be Next - Bloomberg
Teva Pharmaceutical to sell assets such as women's health unit to cut debt | Mint
Teva Raises $2.1 Billion in Debt Tender Offer | Ctech
Should We Be Cautious About Teva Pharmaceutical Industries Limited's (NYSE: TEVA) ROE Of 4.1%? - Simply Wall St News
The Perfect Storm – Teva – Part 1 – GlobalStockPicking.com
Teva's Working With Evercore to Review Debt Options - Bloomberg
Teva announces debt recycling measures - Globes
Billionaire Businessman Looking to Take Stake in Debt-Ridden Teva | BioSpace
Teva's Recovery Hopes Mired in Staggering Antitrust Lawsuit, $26.7 Billion Debt | The Jewish Press - JewishPress.com | David Israel | 7 Iyyar 5779 – May 12, 2019 | JewishPress.com
Investors question green tint of Teva's $5bn sustainability bond | Financial Times
Teva: The Road To Perdition Has Turned Into A Path Towards Redemption (NYSE: TEVA) | Seeking Alpha
